Search Results - "Selleslach, J"

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients by Huygh, G, Clement, Paul M J, Dumez, H, Schöffski, P, Wildiers, H, Selleslach, J, Jimeno, J M, Wever, I De, Sciot, R, Duck, L, Van Oosterom, A T

“…Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma…”
Get full text

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours by Schöffski, P, Awada, A, Dumez, H, Gil, T, Bartholomeus, S, Selleslach, J, Taton, M, Fritsch, H, Peter, N, Munzert, G

Get full text

Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors by Gil, T., Schöffski, P., Awada, A., Dumez, H., Bartholomeus, S., Selleslach, J., Taton, M., Fritsch, H., Glomb, P., Munzert, G. M.

“…Abstract only…”
Get full text

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors by SOEPENBERG, Otto, DUMEZ, Herlinde, LEFEBVRE, Patricia, ASSADOURIAN, Sylvie, SANDERINK, Ger-Jan, SPARREBOOM, Alex, VAN OOSTEROM, Allan T, VERWEIJ, Jaap, DE JONG, Floris A, DE JONGE, Maja J. A, THOMAS, José, ESKENS, Ferry A. L. M, VAN SCHAIK, Ron H. N, SELLESLACH, Johan, TER STEEG, Judith

“…Purpose: To characterize the maximum-tolerated dose, recommended dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and food effect of orally…”
Get full text

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors by SOEPENBERG, Otto, DUMEZ, Herlinde, SPARREBOOM, Alex, VAN OOSTEROM, A. T, VERWEIJ, Jaap, SEMIOND, Dorothee, DEJONGE, Maja J. A, ESKENS, Ferry A. L. M, TER STEEG, Judith, SELLESLACH, Johan, ASSADOURIAN, Sylvie, SANDERINK, Ger-Jan

“…To assess the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary antitumor activity of oral irinotecan given in combination with…”
Get full text

Tumor control and objective responses: single-center experience with ecteinascidin-743 (ET-743), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas by Schöffski, P., Huygh, G., Clement, P., Jimeno, J. M., Wildiers, H., Dumez, H., Selleslach, J., Sciot, R., de Wever, I., van Oosterom, A. T.

“…Abstract only…”
Get full text